All In Biotech

Drug Trial Radar · NCT07264595

A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD)

A Study to Evaluate the Safety and Tolerability of Multiple Ascending Doses of GS3-007a Dry Suspension in Patients With PGHD and to Evaluate the Efficacy and Safety of 52-week of Treatment With GS3-007a Dry Suspension: a Two-part, Multicenter, Randomized, Phase Ib/II Clinical Trial

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Jan 18, 2026

Primary completion

Nov 2030

Study completion Nov 2030

Sponsor

Sponsor type
Industry
First posted
Dec 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part clinical study for children with growth hormone deficiency. In the first part, participants will be randomly assigned to receive different doses of an oral treatment (GS3-007a dry suspension) or a placebo for 14 days. This part is double-blinded, meaning neither the participants nor the doctors will know who is receiving the treatment or placebo. The goal is to find a safe and well-tolerated dose. In the second part, participants will be randomly assigned to receive either the selected dose of GS3-007a or another approved treatment for 52 weeks. This part is open-label, so everyone will know which treatment is being given. After that, all participants may continue taking GS3-007a for another 156 weeks in an extension phase to study long-term effects.

Conditions

  • Pediatric Growth Hormone Deficiency

Interventions

  • GS3-007a dry suspensionDrug

    GS3-007a

  • Placebo for GS3-007a dry suspensionDrug

    Placebo for GS3-007a dry suspension

  • rhGH injectionDrug

    rhGH injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: up to 21 days (Ib phase)
  2. Annualized height velocity (AHV) at Week 26 of treatmentTime frame: 26 weeks (II phase)
  3. Number of Participants With TEAEsTime frame: up to 160 weeks (II phase extension)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.